StratifAI key facts
- Developer of a precision oncology platform designed to advance cancer diagnostics through next-generation biomarker discovery.
- It has raised $16.3M; the latest was Accelerator/Incubator in Oct 2025.
- Notable investors include Creative Destruction Lab, Picus Capital, Alven Capital Partners, Memorial Sloan Kettering Cancer Center, Jens Begemann — 14 tracked in total.
- Status: Privately Held (backing).
Who backs StratifAI
14+- ·The complete investor list: 14 names
- ·Watch StratifAI: the Monday email on marks, rounds and moves
StratifAI funding rounds
No funding rounds for StratifAI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
StratifAI investors
14 investors are on record for StratifAI, including Creative Destruction Lab, Picus Capital, Alven Capital Partners and Memorial Sloan Kettering Cancer Center.
About StratifAI
Developer of a precision oncology platform designed to advance cancer diagnostics through next-generation biomarker discovery. The company offers a multimodal AI discovery platform that identifies prognostic and predictive biomarkers from clinical data and assesses metastatic risk in early breast cancer from digitized histology slides, enabling clinicians in solid-tumor oncology to refine treatment strategies with greater accuracy and equity.
- Sector
- Healthcare
- HQ
- Berlin, Germany
- Founded
- 2023
- Employees
- 18
- Website
- stratifai.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
StratifAI doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.